| Document |
Document Title |
|
WO/2008/152333A9 |
The invention relates to novel derivatives of 3-phenyl propanoic acid of the following general formula (I), to a method for preparing the same, and to the use thereof in pharmaceutical compositions used in human or veterinary medicine (i...
|
|
WO/2009/145219A1 |
Disclosed is a means for treating Alzheimer's disease, which utilizes a secretase inhibitor and is highly safe. Specifically disclosed is a compound represented by general formula (I) [wherein A represents a phenyl group or the like; R1...
|
|
WO/2009/145989A2 |
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...
|
|
WO/2009/144344A2 |
Compound for labelling biomolecules based on vinylsulphone, preparation and uses, comprising a labelling molecule and a vinylsulphone group. In addition it relates to the use of the compounds as labelling agents, to the procedure of obta...
|
|
WO/2009/142984A1 |
Disclosed is a compound of formula (I). Wherein R1, R2 Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the c...
|
|
WO/2009/138758A2 |
There is provided compounds of formula (I), wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of disease...
|
|
WO/2009/136608A1 |
Disclosed is an ionic liquid having a low viscosity, a low melting point, high electrical conductivity and high thermal stability. The ionic liquid is composed of fluorosulfonyl(trifluoromethylsulfonylamide) (FTA) anions and cations of ...
|
|
WO/2009/136617A1 |
Disclosed is a process for producing a compound having an antagonistic activity on a NPYY5 receptor. Also disclosed is a useful crystal. A compound represented by formula (II) [wherein R1 represents a substituted or unsubstituted alkyl;...
|
|
WO/2009/131065A1 |
Disclosed is a compound useful as a prophylactic agent or a therapeutic agent for cardiovascular diseases, nervous system diseases, metabolic diseases, genital diseases, gastrointestinal diseases, neoplasm, infectious diseases and others...
|
|
WO/2009/128088A2 |
The present patent application relates to a process for the preparation of 2-(2-Alkoxy phenoxy) ethylamine or a salt thereof, which is a useful intermediate in the preparation of several active pharmaceutical ingredients including Carved...
|
|
WO/2009/129246A2 |
This invention relates to compositions, methods for preparing the compositions and methods for treating or preventing diseases, comprising administering the compositions.
|
|
WO/2009/127723A1 |
The invention relates to substituted arylsulphonylglycine derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as in the specification and claims, which are suitable for preparing a pharmaceutical compositi...
|
|
WO/2009/127822A2 |
There is provided compounds of formula I, wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases ...
|
|
WO/2009/125606A1 |
Provided is a compound represented by formula (I) having a PAI-1 inhibiting action. [In formula (I), R1 represents an optionally substituted C6-10 aryl group etc., T represents a single bond etc., m is 0 or 1, when m is 0 G represents -N...
|
|
WO/2009/124962A2 |
The invention relates to compounds of formula (I) wherein R1, R2, R4, Ra, Rb, Rc, Re, A*, W1, W2 and W3 are as defined in claim 1, for the treatment of CXCR3 related diseases.
|
|
WO/2009/124022A1 |
The invention provides amino- and amido-aminotetralin compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opio...
|
|
WO/2009/119858A1 |
Disclosed is a novel benzene compound which has an excellent immunosuppressing activity, an excellent rejection-inhibiting effect and others, and is reduced in adverse side effects including bradycardia. Specifically disclosed is a compo...
|
|
WO/2009/118168A1 |
The invention relates to compounds which have an affinity to the ยต-opioid receptor and ORL1 receptor, to processes for preparation thereof, to medicaments comprising these compounds and to the use of these compounds for producing medica...
|
|
WO/2009/118292A1 |
The present invention provides a compound of formula (I):said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by a...
|
|
WO/2009/115257A1 |
The invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicament containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.
|
|
WO/2009/111280A1 |
Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treat...
|
|
WO/2009/111279A1 |
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, ...
|
|
WO/2009/106361A2 |
The present invention provides novel compounds that inhibit cell proliferation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition hyperproliferation.
|
|
WO/2009/103778A1 |
A compound of formula (1) as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment of disorder selected from pain, fever, inflammation and ca...
|
|
WO/2009/105751A1 |
The present disclosure relates to acylsulfonamides and processes for their preparation. The processes involve a target-guided synthesis approach, whereby a thioacid and a sulfonyl azide are reacted in the presence of a biological target ...
|
|
WO/2009/101201A2 |
The object of the present invention is mixtures of ionic and/or like hydrides and ionic liquids and use of such mixtures.
|
|
WO/2009/100095A1 |
Compounds according to the formula below are disclosed herein: Therapeutic methods for the treatment of pain, compositions, and medicaments related thereto are also disclosed.
|
|
WO/2009/096198A1 |
Disclosed is a novel biaryl derivative useful as an anti-cancer drug. A biaryl derivative represented by formula (I), or a pharmacologically acceptable salt thereof. [In formula (I), X represents an amino group substituted, for example, ...
|
|
WO/2009/096526A1 |
Provided is a compound having a CRTH2 antagonism and being useful as a preventive and/or remedy for inflammatory diseases (for example, asthma, allergic rhinitis, allergic dermatitis, conjunctivitis, urticaria, eosinophilic bronchitis, f...
|
|
WO/2009/096701A2 |
This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. Th...
|
|
WO/2009/092712A1 |
This invention relates to by novel N-(phenyl-1, 3-cyclopentyl)sulphonamide derivatives formula (I) and salts thereof: wherein R1 to R9 and p are as defined in the description. The invention also relates to the use of the derivatives in t...
|
|
WO/2009/092713A1 |
This invention relates to novel N-(2-methyl-phenyl-cyclopentyl)sulphonamide derivatives of formula (I) and salts thereof: wherein R1, R2, R3, R4, R5, R6, R7, R8, p, R9 and R10 are as defined in the description. The invention also relates...
|
|
WO/2009/089192A1 |
The present invention provides novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. The compounds are of the general formula (I):
|
|
WO/2009/087085A2 |
A compound of the formula (I) where W is N, NO, or C-R3; X is N, NO or C-R4; Y is N, NO, or C-R5; A is, for example, NR1R6; R1 and R6, independently of each other, are selected, for example, from the group consisting of H and C1-C6-alkyl...
|
|
WO/2009/085177A1 |
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/...
|
|
WO/2009/082347A1 |
The invention provides compounds of formula (I) wherein R1,R3,L1,L2,G1,G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with pro...
|
|
WO/2009/080637A1 |
Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R1 is selected from phenyl and pyridyl, each of which is optionally substituted by one or two groups independently selected from C1-4alkyl and halogen; a...
|
|
WO/2009/081956A1 |
Disclosed is a method for producing a conjugated aromatic compound, which is characterized in that an aromatic compound (A) having one or two leaving groups bonded to an aromatic ring is reacted with another aromatic compound (A) having ...
|
|
WO/2009/080722A2 |
The invention provides novel compounds of formula (I), wherein: R1 is a radical derived from one of the known ring systems; R2 is a phenyl radical optionally substituted; Xn represents a birradical selected from the group consisting of: ...
|
|
WO/2009/079375A1 |
Novel histone deacetylase inhibitors, including novel fluorescent histone deacetylase inhibitors, are described. Methods for making and using the same, e.g., to treat cancer, are provided.
|
|
WO/2009/073427A1 |
The invention provides novel aryl and aliphatic esters of fluorinated alkanesulfonic acids. The invention also provides novel fluorinated alkanesulfonamides and a process to make the same. The invention also provides a process for the ar...
|
|
WO/2009/071947A2 |
Compounds of formula (I) and pharmacologically acceptable salts wherein: Ar1 and Ar2 = aryl or heteroaryl; are excellent selective modulators of potassium ion flux.through KCNQ2, KCNQ3 and/or KCNQ2/3 channels, making them of use in treat...
|
|
WO/2009/067597A1 |
Compounds of the formula: (I) are disclosed. The compounds act as phosphodiesterase-4 modulators, and useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions. Other embodiments are also disclosed.
|
|
WO/2009/066035A2 |
Combination of an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor (ACEI), and also pharmaceutical compositions containing same. Medicaments
|
|
WO/2009/064449A1 |
Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including huma...
|
|
WO/2009/064250A1 |
The invention provides compounds of formula wherein R1, R2 , R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for...
|
|
WO/2009/064251A1 |
The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with pr...
|
|
WO/2009/061652A1 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating ...
|
|
WO/2009/055917A1 |
ABSTRACT OF THE DISCLOSURE This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharm...
|
|
WO/2009/053281A1 |
A process for the preparation of cyclopropyl sulfonamide of the formula (I) is described, comprising (a) the conversion of cyclopropane sulfonyl chloride with tert.-butylamine to form the N-tert.-butyl-3-chloropropyl sulfonamide; (b) sub...
|
